Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 106, Issue 1, 2008, Pages

  Utsman, Robert A ^a   Epstein, Joel B ^b   Elad, Sharon ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Department of Oral Medicine and Diagnostic Sciences   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BUDESONIDE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CASE REPORT; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; LYMPHATIC LEUKEMIA; MALE; MIDDLE AGED; MOUTH DISEASE; MOUTH MUCOSA; MOUTHWASH; MUCOCELE; NEUTROPHIL CHEMOTAXIS; PARANEOPLASTIC SYNDROME; PEMPHIGUS;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOID; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH MUCOSA; MOUTHWASHES; MUCOCELE; NEUTROPHIL INFILTRATION; PARANEOPLASTIC SYNDROMES; PEMPHIGUS;

EID: 45949100806     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.02.029     Document Type: Article

References (19)

1. Taintor A.R., Leiferman K.M., Hashimoto T., Ishii N., Zone J.J., and Hull C.M. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J Am Acad Dermatol 56 5 Suppl (2007) S73-S76
2. Favia G.F., Di Alberti L., and Piattelli A. Paraneoplastic pemphigus: a report of two cases. Oral Oncol 34 6 (1998) 571-575
3. Anhalt G.J., Kim S.C., Stanley J.R., Korman N.J., Jabs D.A., Kory M., et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323 25 (1990) 1729-1735
4. Schubert M.M., and Correa M.E. Oral GVHD. Dent Clin North Am 52 1 (2008) 79-109
5. Mattsson T., Sundqvist K.G., Heimdahl A., Dahllof G., Ljungman P., and Ringden O. A comparative immunological analysis of the oral mucosa in chronic graft-versus-host disease and oral lichen planus. Arch Oral Biol 37 (1992) 539-547
6. Spencer C.M., and McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50 5 (1995) 854-872
7. Rutgeerts P., Lofberg R., Malchow H., Lamers C., Olaison G., Jewell D., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331 13 (1994) 842-845
8. Eckardt A., Starke O., Stadler M., Reuter C., and Hertenstein B. Severe oral chronic graft-versus- host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40 8 (2004) 811-814
9. Albert M.H., Becker B., Schuster F.R., Klein B., Binder V., Adam K., et al. Oral graft vs. host disease in children: treatment with topical tacrolimus ointment. Pediatr Transplant 11 3 (2007) 306-311
10. Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 12 (2005) 945-956
11. Hellers G., Cortot A., Jewell D., Leijonmarck C.E., Lofberg R., Malchow H., et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 116 2 (1999) 294-300
12. Lofberg R., Danielsson A., Suhr O., Nilsson A., Schioler R., Nyberg A., et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110 6 (1996) 1713-1718
13. Sari I., Altuntas F., Kocyigit I., Sisman Y., Eser B., Unal A., et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82 5 (2007) 349-356
14. Elad S., Or R., Garfunkel A.A., and Shapira M.Y. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 3 (2003) 308-311
15. Dahlberg E., Thalen A., Brattsand R., Gustafsson J.A., Johansson U., Roempke K., et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 25 1 (1984) 70-78
16. Borradori L., Lombardi T., Samson J., Girardet C., Saurat J.H., and Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 137 3 (2001) 269-272
17. Hoque S.R., Black M.M., and Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin Exp Dermatol 32 2 (2007) 172-175
18. Elad S., Or R., Haviv A., and Shapira M.Y. The therapeutic potential of budesonide for oral mucosal diseases. In: Dignass A. (Ed). Proceedings of Falk Symposia: New findings on pathogenesis and progress in management of inflammatory bowel diseases (2004), Kluwer Academic Publishers, Dordrecht, The Netherlands 74-84
19. McCarthy T.P. Oral ulcer responds well to potent topical steroid. Br Dent J 170 3 (1991) 90